9 10, 2026

What does a positive test result really mean? Try our Predictive Value Explorer

2026-10-09T11:26:04+02:00October 9th, 2026|biomarker, diagnostics, IVD|0 Comments

A test with 90% sensitivity and 90% specificity sounds reliable. But use it for screening, where 1 in 100 people has the disease, and fewer than 1 in 10 positive results will be true positives. Our new Predictive Value Explorer shows why. Sensitivity and specificity describe how well a test detects disease in samples with a known diagnosis. Patients and doctors ask a different question: if the result is positive, how likely is it that I have the disease? The positive and negative predictive values (PPV and NPV) answer that question. They depend on a third number: the prevalence, or pre-test probability, of the disease in the people being tested. When the pre-test probability is low, as [...]

22 09, 2026

New evidence on variability of plasma miR-122 published with contribution of TAmiRNA

2026-09-22T10:58:24+02:00September 22nd, 2026|biomarker, circulating miRNAs, DILI, drug-induced liver injury, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA, TransBioLine|Comments Off on New evidence on variability of plasma miR-122 published with contribution of TAmiRNA

A short communication published in the British Journal of Clinical Pharmacology re-evaluates the inter- and intra-individual variability of circulating miR-122 in healthy volunteers, using small RNA sequencing generated on TAmiRNA's miND workflow (Javid et al., 2026, doi:10.1002/bcp.70836). Background MicroRNA-122 (miR-122) is a liver-enriched circulating microRNA and one of the most extensively studied candidate biomarkers for drug-induced liver injury (DILI). A 2019 evaluation by Church et al. reported substantial inter- and intra-individual variability of miR-122 in healthy volunteers, which raised questions about its use as a diagnostic biomarker. The present study, conducted within the IMI2 TransBioLine consortium, set out to re-examine this variability in new, independent cohorts. Study and findings Plasma samples from 280 healthy volunteers were collected [...]

8 09, 2026

TAmiRNA Joins Six European RNA Specialists to Launch the European RNA Alliance

2026-09-10T10:01:04+02:00September 8th, 2026|biomarker, circulating miRNAs, ERA, European RNA Alliance, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA|1 Comment

As a founding member of ERA, TAmiRNA positions itself as the innovative driving force behind RNA biomarker development in Europe — combining novel biomarker products with premier research services in cell-free RNA and EV/exosome analysis. Vienna, Austria — September 8, 2026 TAmiRNA is proud to announce that it has joined six other independent European RNA companies — Anemocyte, Genevia Technologies, Immagina Biotechnology, Lexogen, MultiplexDX, and siTOOLS Biotech — as a founding member of the European RNA Alliance (ERA), a new strategic alliance launched today to strengthen Europe's position in high-quality RNA technologies. RNA technologies are increasingly central to modern medicine — diagnostics, disease monitoring, prophylaxis, therapeutics, and personalized treatment. Yet Europe's considerable expertise in this space is [...]

1 09, 2026

TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen

2026-09-01T10:20:37+02:00September 1st, 2026|biomarker, circulating miRNAs, Conference, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA|Comments Off on TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen

From September 28–30, 2026, the D-A-CH EV Meeting 2026 will take place at the Hörsaalzentrum of the Medical Faculty, University Hospital Erlangen — the first joint annual meeting of the German, Austrian and Swiss societies for extracellular vesicles (GSEV, ASEV and SwissEV). Under the motto "Extracellular Vesicles: Communication Across Barriers," around 300 to 350 international scientists from the EV field will gather in Erlangen. The three-day programme covers the full breadth of EV research: from the fundamentals of EV biology, purification and characterization, to methodological advances, microbial EVs, clinical translation, reproducibility and open questions in EV research, as well as novel EV sources and emerging concepts. Keynote lectures, selected abstracts, poster sessions, roundtable discussions and industry presentations [...]

27 08, 2026

TAmiRNA at the 5th MC/WG Meeting of COST Action AtheroNET in Prague

2026-08-27T09:15:39+02:00August 27th, 2026|biomarker, Conference, RNA, small RNA-sequencing, smallRNA|Comments Off on TAmiRNA at the 5th MC/WG Meeting of COST Action AtheroNET in Prague

From September 2–4, 2026, the COST Action AtheroNET (CA21153) network will gather for its 5th Management Committee and Working Group meeting at the University of Chemical Technology in Prague. AtheroNET is supported by COST (European Cooperation in Science and Technology) and connects European research groups working on new approaches to understanding and diagnosing atherosclerosis. The three-day programme promises intensive scientific exchange: from a keynote lecture on B cells and humoral immunity as modulators of residual cardiovascular risk, through sessions from all four Working Groups (cardioprotection and immune mechanisms, omics-based risk stratification, standardisation and ring trials, and AI/multi-omics methods), to two Young Researchers & Innovators sessions and a poster session. We are especially pleased that Dr. Matthias Hackl, [...]

31 07, 2026

TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026

2026-08-27T09:09:04+02:00July 31st, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, RNA, small RNA-sequencing, smallRNA|Comments Off on TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026

Our CEO Dr. Matthias Hackl, a leading expert in microRNA biomarker discovery, small RNA sequencing, and IVD development, has been invited as a lecturer at this year's Jyväskylä Summer School at the University of Jyväskylä, Finland. As part of the course BIO1: MicroRNA Biology and Function (4–6 August 2026), he will join an international team of experts from Helsinki, Kuopio, and Jyväskylä to deliver a lecture on microRNA biomarker discovery, validation, and clinical application, titled: "microRNAs as Biomarkers: Discovery, Validation, and the Path to Clinical Application" Participants will: Understand what constitutes a clinically useful biomarker and how signal-to-noise ratio and pre-analytical, analytical, and biological variability impact biomarker study design Learn how small RNA sequencing (next-generation sequencing, NGS) [...]

11 03, 2026

TAmiRNA @ RNA Leaders Europe Conference

2026-03-11T10:10:00+01:00March 11th, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, NGS, RNA|Comments Off on TAmiRNA @ RNA Leaders Europe Conference

Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, one of the leading industry events dedicated to RNA therapeutics, innovation, and translational research. RNA Leaders Europe brings together key stakeholders from academia, biotech, pharma, and technology providers to discuss the latest scientific advances, regulatory developments, and commercialization strategies in the rapidly evolving RNA field. As a specialized provider of RNA-focused services, TAmiRNA supports partners worldwide with comprehensive solutions ranging from RNA profiling and biomarker discovery to advanced bioinformatics and customized data analysis. The conference offers an excellent platform to exchange insights, explore collaborations, and discuss how cutting-edge [...]

2 03, 2026

Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

2026-03-02T10:12:31+01:00March 2nd, 2026|biomarker, circulating miRNAs, Illumina NewSeq2000, microRNA, microRNA services, NGS, T1D, Type 1 Diabetes|Comments Off on Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D). The study, published in PLOS ONE (2026), strengthens growing evidence that circulating microRNAs serve as minimally invasive biomarkers with potential applications in disease monitoring and precision medicine. Study Overview: microRNA Biomarkers in Adolescent Type 1 Diabetes Reliable biomarkers are essential for improving disease monitoring and long-term management of type 1 diabetes. MicroRNAs — small, non-coding RNA molecules regulating gene expression — are detectable in blood and have emerged as promising non-invasive diagnostic and prognostic tools. This case-control study investigated previously reported circulating miRNAs in: 24 adolescents with type [...]

7 01, 2026

TAmiRNA Research on microRNA Biomarkers for Periprosthetic Joint Infections Featured on Wien Heute, One of Austria’s Most-Watched Regional News Programs

2026-01-21T08:39:17+01:00January 7th, 2026|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on TAmiRNA Research on microRNA Biomarkers for Periprosthetic Joint Infections Featured on Wien Heute, One of Austria’s Most-Watched Regional News Programs

Research conducted by TAmiRNA in collaboration with the Michael Ogon Laboratory (Orthopädisches Spital Speising) on microRNA-based biomarkers for the early detection of periprosthetic joint infections (PJI) was recently featured on Wien Heute, one of Austria’s most widely viewed regional television news programs (ORF, January 3, 2026). The coverage highlights both the clinical relevance of the problem and the translational potential of novel molecular diagnostic approaches. Periprosthetic joint infections are among the most serious complications following hip and knee arthroplasty. Although the incidence is estimated at approximately 1-10%, PJIs are associated with substantial morbidity, prolonged treatment, and high healthcare costs. A major challenge in clinical practice remains the timely and reliable differentiation between infected and non-infected implants, particularly [...]

4 12, 2025

Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

2025-12-04T11:05:09+01:00December 4th, 2025|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

New research highlights the potential of circulating miRNAs as biomarkers for joint degeneration A new peer-reviewed study has been published in the International Journal of Molecular Sciences (IJMS): “Synovial Fluid and Serum MicroRNA Signatures in Equine Osteoarthritis.” This work provides important insights into how microRNAs (miRNAs) in serum and synovial fluid reflect the presence of osteoarthritis (OA) in horses. 🎯 Study Aim The researchers sought to identify disease-associated miRNAs that differ between healthy horses and horses with osteoarthritis. Their goal was to uncover molecular signatures that could support the development of novel biomarkers for early detection and monitoring of OA. 🔬 Methods Serum and synovial fluid samples were collected from healthy controls (n = 4) and horses [...]

Go to Top